Bipolar patients treated with long-acting injectable risperidone in Taiwan

A 1-year mirror-image study using a national claims database

Ming H. Hsieh, Po Ya Chuang, Chi Shin Wu, Ching Jui Chang, Pei Fang Chung, Chao Hsiun Tang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. Method 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007–2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data. The paired t-tests with a correction for multiple comparisons using Bonferroni correction were used to compare the proportion of patients of concomitant psychiatric medication and resource use and costs between pre- and post-RLAI periods. Rapid and non-rapid cycling stratification was performed based on the number of change-in-mood episodes within 1 year prior to the index date. Results The mean annual dose of RLAI was 638.41 mg, which was equal to an average dose of 24.6 mg every 2 weeks. The prevalence of concomitant use of conventional antipsychotics, atypical antipsychotics, lithium, and antidepressants decreased from the pre-RLAI period to the post-RLAI period by 23.75%, 31.91%, 1.29%, and 7.08%, respectively. RLAI use decreased emergency room (ER) visits, hospital admissions, length of hospital stay, and non-medication costs (all P<0.0001). The cost savings with RLAI were attributed to lower hospitalization costs in spite of higher medication costs. Moreover, rapid cycling patients (n=36) demonstrated greater reduction in ER and inpatient services with RLAI than non-rapid cycling patients (n=251). Limitations Of the patients who initiated RLAI, 15% of them who had regular treatment were included. Furthermore, data on measures of symptom severity, side effects, and hyperprolactinemia were not available. Conclusion BD patients had lower inpatient and ER utilization, and non-medication costs after using RLAI. In addition, RLAI use decreased the number of change-in-mood episodes in rapid cycling patients; which provides additional insights into the treatment of rapid cycling BD patients.

Original languageEnglish
Pages (from-to)327-334
Number of pages8
JournalJournal of Affective Disorders
Volume218
DOIs
Publication statusPublished - Aug 15 2017

Fingerprint

Risperidone
Taiwan
Databases
Injections
Bipolar Disorder
Costs and Cost Analysis
Hospital Emergency Service
Antipsychotic Agents
Inpatients
Length of Stay
Hyperprolactinemia
Cost Savings
National Health Programs
Therapeutics
Lithium
Health Care Costs
Antidepressive Agents
Psychiatry
Hospitalization

Keywords

  • Bipolar disorder
  • Costs
  • Healthcare utilization
  • Mirror-image
  • RLAI

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Bipolar patients treated with long-acting injectable risperidone in Taiwan : A 1-year mirror-image study using a national claims database. / Hsieh, Ming H.; Chuang, Po Ya; Wu, Chi Shin; Chang, Ching Jui; Chung, Pei Fang; Tang, Chao Hsiun.

In: Journal of Affective Disorders, Vol. 218, 15.08.2017, p. 327-334.

Research output: Contribution to journalArticle

@article{56bc4b61355c473ba1bd73efae69317a,
title = "Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database",
abstract = "Objective Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. Method 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007–2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data. The paired t-tests with a correction for multiple comparisons using Bonferroni correction were used to compare the proportion of patients of concomitant psychiatric medication and resource use and costs between pre- and post-RLAI periods. Rapid and non-rapid cycling stratification was performed based on the number of change-in-mood episodes within 1 year prior to the index date. Results The mean annual dose of RLAI was 638.41 mg, which was equal to an average dose of 24.6 mg every 2 weeks. The prevalence of concomitant use of conventional antipsychotics, atypical antipsychotics, lithium, and antidepressants decreased from the pre-RLAI period to the post-RLAI period by 23.75{\%}, 31.91{\%}, 1.29{\%}, and 7.08{\%}, respectively. RLAI use decreased emergency room (ER) visits, hospital admissions, length of hospital stay, and non-medication costs (all P<0.0001). The cost savings with RLAI were attributed to lower hospitalization costs in spite of higher medication costs. Moreover, rapid cycling patients (n=36) demonstrated greater reduction in ER and inpatient services with RLAI than non-rapid cycling patients (n=251). Limitations Of the patients who initiated RLAI, 15{\%} of them who had regular treatment were included. Furthermore, data on measures of symptom severity, side effects, and hyperprolactinemia were not available. Conclusion BD patients had lower inpatient and ER utilization, and non-medication costs after using RLAI. In addition, RLAI use decreased the number of change-in-mood episodes in rapid cycling patients; which provides additional insights into the treatment of rapid cycling BD patients.",
keywords = "Bipolar disorder, Costs, Healthcare utilization, Mirror-image, RLAI",
author = "Hsieh, {Ming H.} and Chuang, {Po Ya} and Wu, {Chi Shin} and Chang, {Ching Jui} and Chung, {Pei Fang} and Tang, {Chao Hsiun}",
year = "2017",
month = "8",
day = "15",
doi = "10.1016/j.jad.2017.04.074",
language = "English",
volume = "218",
pages = "327--334",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Bipolar patients treated with long-acting injectable risperidone in Taiwan

T2 - A 1-year mirror-image study using a national claims database

AU - Hsieh, Ming H.

AU - Chuang, Po Ya

AU - Wu, Chi Shin

AU - Chang, Ching Jui

AU - Chung, Pei Fang

AU - Tang, Chao Hsiun

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Objective Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. Method 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007–2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data. The paired t-tests with a correction for multiple comparisons using Bonferroni correction were used to compare the proportion of patients of concomitant psychiatric medication and resource use and costs between pre- and post-RLAI periods. Rapid and non-rapid cycling stratification was performed based on the number of change-in-mood episodes within 1 year prior to the index date. Results The mean annual dose of RLAI was 638.41 mg, which was equal to an average dose of 24.6 mg every 2 weeks. The prevalence of concomitant use of conventional antipsychotics, atypical antipsychotics, lithium, and antidepressants decreased from the pre-RLAI period to the post-RLAI period by 23.75%, 31.91%, 1.29%, and 7.08%, respectively. RLAI use decreased emergency room (ER) visits, hospital admissions, length of hospital stay, and non-medication costs (all P<0.0001). The cost savings with RLAI were attributed to lower hospitalization costs in spite of higher medication costs. Moreover, rapid cycling patients (n=36) demonstrated greater reduction in ER and inpatient services with RLAI than non-rapid cycling patients (n=251). Limitations Of the patients who initiated RLAI, 15% of them who had regular treatment were included. Furthermore, data on measures of symptom severity, side effects, and hyperprolactinemia were not available. Conclusion BD patients had lower inpatient and ER utilization, and non-medication costs after using RLAI. In addition, RLAI use decreased the number of change-in-mood episodes in rapid cycling patients; which provides additional insights into the treatment of rapid cycling BD patients.

AB - Objective Bipolar disorder (BD) is burdensome for patients and healthcare systems. This study evaluated changes in concomitant medication patterns, healthcare utilization, and costs after the initiation of risperidone long-acting injection (RLAI) treatment among BD patients. Method 287 BD patients receiving regular RLAI treatment for 1 year were identified from the Taiwan National Health Insurance Research database during 2007–2012. The bootstrapping procedure was performed to create 1000 samples to generate normally distributed data. The paired t-tests with a correction for multiple comparisons using Bonferroni correction were used to compare the proportion of patients of concomitant psychiatric medication and resource use and costs between pre- and post-RLAI periods. Rapid and non-rapid cycling stratification was performed based on the number of change-in-mood episodes within 1 year prior to the index date. Results The mean annual dose of RLAI was 638.41 mg, which was equal to an average dose of 24.6 mg every 2 weeks. The prevalence of concomitant use of conventional antipsychotics, atypical antipsychotics, lithium, and antidepressants decreased from the pre-RLAI period to the post-RLAI period by 23.75%, 31.91%, 1.29%, and 7.08%, respectively. RLAI use decreased emergency room (ER) visits, hospital admissions, length of hospital stay, and non-medication costs (all P<0.0001). The cost savings with RLAI were attributed to lower hospitalization costs in spite of higher medication costs. Moreover, rapid cycling patients (n=36) demonstrated greater reduction in ER and inpatient services with RLAI than non-rapid cycling patients (n=251). Limitations Of the patients who initiated RLAI, 15% of them who had regular treatment were included. Furthermore, data on measures of symptom severity, side effects, and hyperprolactinemia were not available. Conclusion BD patients had lower inpatient and ER utilization, and non-medication costs after using RLAI. In addition, RLAI use decreased the number of change-in-mood episodes in rapid cycling patients; which provides additional insights into the treatment of rapid cycling BD patients.

KW - Bipolar disorder

KW - Costs

KW - Healthcare utilization

KW - Mirror-image

KW - RLAI

UR - http://www.scopus.com/inward/record.url?scp=85018382679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018382679&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2017.04.074

DO - 10.1016/j.jad.2017.04.074

M3 - Article

VL - 218

SP - 327

EP - 334

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -